AstraZeneca taps Biologics to distribute carcinoma drug
Biologics Inc., a McKesson Specialty Health oncology pharmacy services company, has been chosen by AstraZeneca to distribute Imfinzi. Read More »
Amgen and UCB release positive results for Evenity study
Amgen and UCB recently announced that their Evenity study, which analyzed the drug as a treatment for postmenopausal women with osteoporosis, met both primary endpoints and the secondary endpoint. Read More »
Therigy partners with EPI-W to expand research on specialty pharmacy outcomes
Therigy, a company that pioneered patient-focused specialty therapy management, recently announced a strategic partnership with EPI-Q Inc. to expand research on specialty pharmacy outcomes. Read More »
FDA approves Sanofi's Kevzara for rheumatoid arthritis treatment
Sanofi and Regeneron Pharmaceuticals Inc. recently announced that Kevzara (sarilumab), a treatment for adult patients with moderately to severely active rheumatoid arthritis who have not responded well to one or more disease modifying antirheumatic drugs, has been approved by the U.S. Food and Drug Administration. Read More »
Good Neighbor Pharmacy network adds fee estimator tool
Pharmaceutical provider AmerisourceBergen recently unveiled the DIR Fee Estimator, its newest tool in conjunction with its nationwide Good Neighbor Pharmacy network, to streamline transactions between provider networks and pharmacy benefit managers by providing cost estimate ranges. Read More »
FDA clears first neonatal MRI device
To better tend babies in the nation’s neonatal intensive care units, the first magnetic resonance imaging (MRI) device designed for newborns recently garnered U.S. Food and Drug Administration approval following thorough safety confirmation. Read More »
FDA accepts Amgen’s BLA for Aimovig (erenumab)
California-based Amgen recently obtained U.S. Food and Drug Administration (FDA) acceptance of its Biologics License Application (BLA) for Aimovig (erenumab), a product developed specifically to help victims of frequent migraine headaches. Read More »
Chinese officials accept study application for GBM treatment
DelMar Pharmaceuticals' application for a Phase II study evaluating a treatment for newly diagnosed MGMT-unmethylated glioblastoma multiforme has been accepted by the Human Genetic Resources Administration of China. Read More »
Luminex Corp.'s c. difficile assay attains FDA clearance
Luminex Corporation recently announced that its ARIES clostridium difficile (c. difficile) assay has been given U.S. Food and Drug Administration (FDA) clearance. Read More »
Health Canada to review Sunovion's schizophrenia treatment
Sunovion Pharmaceuticals Inc. of Marlborough, Massachusetts recently gained approval for its supplemental new drug submission regarding Latuda (lurasidone HCI) — aimed at relieving adolescent schizophrenia — from Health Canada, potentially extending the treatment’s age range. Read More »
European agency approves Tocagen's treatment for high grade glioma
Tocagen Inc., a clinical-stage, cancer-selective gene therapy company, recently announced that its Toca 511 was awarded PRIME designation by the European Medicines Agency for treating high grade glioma patients. Read More »
Accord acquires rights to sell Custodiol HTK Solution
Accord Healthcare has acquired Essential Pharmaceuticals, a New Jersey company that provides products, services and contributions to transplant medicine. Read More »
Merck launches Renflexis as biosimilar with FDA consent
New Jersey-based Merck recently introduced Renflexis (infliximab-abda) in the United States as a biosimilar of Remicade (infliximab) following its FDA approval last April for all eligible indications. Read More »
Lexicon and Ipsen's MAA for Xermelo given positive opinion by CHMP
Lexicon Pharmaceuticals Inc.'s Xermelo, a carcinoid syndrome diarrhea treatment created in collaboration with Ipsen, has been given a positive opinion for Marketing Authorization Application by the Committee for Medicinal Products for Human Use, the committee of the European Medicines Agency responsible for human medicines. Read More »
Thermo Fisher adds mini implant line to its drug implant development line
Thermo Fisher Scientific Inc. recently announced the availability of a fully integrated solution for polymer-based drug implant development and production using hot melt extrusion (HME). Read More »
Eisai's supplemental application for Fycompa CIII accepted
Eisai Inc.'s supplemental New Drug Application for Fycompa CIII has been accepted by the U.S. Food and Drug Administration. Read More »
Pfizer's Avastin biosimilar meets primary endpoint in study
Pfizer Inc. recently announced positive results for its Reflections B7391003 study, which evaluated the safety and efficacy of PF-06439535 as compared to Avastin (bevacizumab). Read More »
Gilteritinib gains orphan-drug status to combat AML
Because acute myeloid leukemia (AML) impacts relatively few individuals nationwide, gilteritinib — an anti-cancer medication developed by Tokyo-based Astellas Pharma Inc. — recently attained orphan-drug designation from the U.S. Food and Drug Administration. Read More »
EnvisionRx receives renewed accreditation from URAC
EnvisionRx, a pharmacy benefit manager (PBM) and division of EnvisionRxOptions, a wholly owned subsidiary of Rite Aid Corporation, recently announced that the health care accrediting organization URAC renewed the company’s accreditation for pharmacy benefit management. Read More »
Vizient releases Drug Price Forecast for 2018
Vizient Inc. recently released its July 2017 Drug Price Forecast, which provides pharmacy leaders and health system executives with insights on pricing and practice changes throughout the pharmaceutical industry. Read More »
Alerts Sign-up